Neuphoria Therapeutics Inc.
NEUP
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.95M
Close$
Share Statistics
| Market cap | $4.95 Million |
|---|---|
| Enterprise Value | $-14,485,716.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -1314.21% |
|---|---|
| Return on Assets | -1110.89% |
| Return on Invested Capital | -2575.09% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.92 |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$996,483
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bionomics Ltd.
1 employees
CEO: Spyridon Papapetropoulos Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals l...